Table 3.
Glycemic Outcomes in the Full Closed-Loop Therapy (RocketAP) Using Different Insulin Analogs for the Baseline and Adjusted In Silico Scenarios
| Baseline—RocketAP |
Adjusted—RocketAP |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Postprandial |
Overall |
Postprandial |
Overall |
|||||||||
| Asparta | Fiasp | AT-247 | Asparta | Fiasp | AT-247 | Asparta | Fiasp | AT-247 | Asparta | Fiasp | AT-247 | |
| Average of BG levels (mg/dL) | 186.6 (46.4) | 185.1 (45.6) | 182.8 (44.4) | 162.7 (50.6) | 162 (49.3) | 161 (47.5) | 186.6 (46.4) | 178.4 (43.5) | 171.7 (40) | 162.7 (50.6) | 155.8 (46.6) | 150.5 (42.3) |
| Time spent <54 mg/dL (%) | 0 (0.1) | 0 (0) | 0 (0) | 0 (0.2) | 0 (0.1)b | 0 (0)b | 0 (0.1) | 0 (0.1) | 0 (0.2) | 0 (0.2) | 0.1 (0.4) b | 0.1 (0.5) b |
| Time spent <70 mg/dL (%) | 0.1 (0.5) | 0.1 (0.4) | 0 (0.2) | 0.4 (1.6) | 0.2 (1.1)c | 0.1 (0.4)c | 0.1 (0.5) | 0.2 (0.9) | 0.2 (1) | 0.4 (1.6) | 0.5 (1.9) b | 0.4 (1.9) b |
| Time spent in 70–140 mg/dL (%) | 15.5 (13.5) | 15.8 (13.9) | 16.4 (14.9) | 39.4 (21) | 40.1 (21.4)c | 41 (22.1)c | 15.5 (13.5) | 18.9 (15.7) | 21.6 (17.6) | 39.4 (21) | 43.8 (21.5)c | 47.4 (21.8)c |
| Time spent in 70–180 mg/dL (%) | 46.8 (30.1) | 48.6 (31.2) | 51.2 (33) | 64.7 (25.7) | 65.9 (26.3)c | 67.8 (27.2)c | 46.8 (30.1) | 53.8 (31.2) | 60.5 (32.2) | 64.7 (25.7) | 70.1 (24.8)c | 75.3 (23.6)c |
| Time spent >180 mg/dL (%) | 53.1 (30.2) | 51.3 (31.2) | 48.7 (33.1) | 34.9 (25.8) | 33.9 (26.3)c | 32.2 (27.3)c | 53.1 (30.1) | 46 (31.3) | 39.3 (32.3) | 34.9 (25.8) | 29.4 (25)c | 24.3 (23.8)c |
| Time spent >250 mg/dL (%) | 9.2 (21.1) | 8.6 (20.8) | 7.9 (20.4) | 5.7 (14.3) | 5.4 (14.2)c | 5 (14)c | 9.2 (21.1) | 6.2 (17.3) | 3.8 (12.9) | 5.7 (14.4) | 3.7 (11)c | 2.1 (7.7)c |
| Coefficient of variation of BG levels (%) | 16.4 (4.1) | 15.7 (3.9) | 14.7 (3.3) | 23.5 (5.4) | 22.5 (5) | 21 (4.4) | 16.4 (4.2) | 16.3 (4.4) | 15.5 (4.3) | 23.5 (5.4) | 22.8 (5.4) | 21.6 (5.2) |
| Insulin delivered (U) | 33.4 (16.8) | 33.4 (16.8) | 33.3 (16.8) | 49.3 (25.9) | 49.4 (26) | 49.7 (26.1) | 33.4 (16.8) | 35.3 (17.7) | 36.8 (18) | 49.3 (25.9) | 51.3 (26.8) | 52.9 (27.5) |
Results presented as mean (standard deviation).
a
Aspart in both baseline and adjusted scenario were the same since (Aspart) corresponds to the optimal tuning for this insulin analog. However, the metrics are repeated to facilitate comparison in both cases.
b
No statistically significant differences in glycemic metrics when switching from Aspart to Fiasp or AT247 for the overall period (P > 0.05).
c
Statistically significant differences in glycemic metrics when switching from Aspart to Fiasp or AT247 for the overall period (P < 0.05).